Allergan Readies Cost Cuts As Restasis Generics Approach
Executive Summary
Allergan is working on a plan to reduce costs now that Restasis generics could hit the US market in 2018, but the company said sales growth for other drugs coupled with new product launches will boost revenue even if the dry eye drug loses its blockbuster status.
You may also be interested in...
Allergan's Restasis Defense Falters As PTAB Dismisses Tribal Immunity Ploy
The damage inflicted by Mylan and other manufacturers looking to sell Restasis generics already has been felt by Allergan, but the PTAB dealt the dry eye drug's patent defense another blow by rejecting the Mohawk Tribe's plea to have an inter partes review thrown out.
Allergan's Restasis Defense Falters As PTAB Dismisses Tribal Immunity Ploy
The damage inflicted by Mylan and other manufacturers looking to sell Restasis generics already has been felt by Allergan, but the PTAB dealt the dry eye drug's patent defense another blow by rejecting the Mohawk Tribe's plea to have an inter partes review thrown out.
Mohawk Tribe Is Not Immune To IPR (And Allergan Really Owns Restasis Patents Anyway) PTAB Decrees
Allergan's novel tactic to derail inter partes review of Restasis patents ends for now as Patent Trial and Appeal Board denies Tribe's request to terminate proceeding; Board sets June 6 deadline for final written decision on IPR petition.